Background and Purpose
Doxorubicin is a broad-spectrum antineoplastic agent; however, its
genotoxic/cytotoxic effects limit its clinical application. Dimethyl
Fumarate is an FDA-approved to treat multiple sclerosis shown to have
antioxidant, anti-inflammatory and antimutagenic effects via activating
Nrf2 pathway. The present study aimed to investigate the possible
protective effect of DMF against doxorubicin-induced chromosomal and DNA
damage in rat bone marrow cells.